Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 2/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | HSP90AA1 | P07900 | 11/20 | 0.37 |
| ▸ | HSP90AB1 | P08238 | 10/20 | 0.37 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.36 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.35 |
| ▸ | USP2 | O75604 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL428095 | 0.85 | POLB (0.44) | KDM4ETP53HSP90AA1HSP90AB1MAPT | |
| SCHEMBL3114137 | 0.84 | TP53 (0.39) | TP53HSP90AA1HSP90AB1 | |
| SCHEMBL3103709 | 0.80 | PIK3CA (0.40) | KDM4ETP53HSP90AA1HSP90AB1PIK3CA | |
| SCHEMBL3116342 | 0.79 | PKM (0.38) | KDM4ESMN1; SMN2TP53HSP90AA1HSP90AB1 | |
| SCHEMBL3111642 | 0.74 | KDM4E (0.41) | KDM4ESMN1; SMN2TP53NPSR1MEN1 | |
| SCHEMBL427614 | 0.72 | TP53 (0.38) | SMN1; SMN2TP53MEN1KMT2APIK3CA | |
| SCHEMBL3120773 | 0.68 | KDM4E (0.48) | KDM4ETSHRSMN1; SMN2CYP3A4CYP2C9 | |
| SCHEMBL304147 | 0.66 | MAPT (0.41) | KDM4ENPSR1MEN1KMT2ACYP3A4 | |
| SCHEMBL304145 | 0.66 | MAPT (0.41) | KDM4ENPSR1MEN1KMT2ACYP3A4 | |
| SCHEMBL11926386 | 0.64 | ALDH1A1 (0.42) | KDM4ESMN1; SMN2TP53MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100256132-A1 | IL-12 MODULATORY COMPOUNDS | SYNTA PHARMACEUTICALS CORPORATION (US) | 2010-10-07 | — | — | US | claimed |
| US-20060223996-A1 | IL-12 modulatory compounds | SYNTA PHARMACEUTICALS CORP. (US) | 2006-10-05 | — | — | US | claimed |
| US-8236795-B2 | IL-12 modulatory compounds | SYNTA PHARMACEUTICALS CORP. (US) | 2012-08-07 | — | — | US | disclosed |
| US-20100256132-A1 | IL-12 MODULATORY COMPOUNDS | SYNTA PHARMACEUTICALS CORPORATION (US) | 2010-10-07 | — | — | US | disclosed |
| US-7696202-B2 | IL-12 modulatory compounds | SYNTA PHARMACEUTICALS CORP. (US) | 2010-04-13 | — | — | US | disclosed |
| EP-1819341-A2 | IL-12 MODULATORY COMPOUNDS | Synta Pharmaceuticals Corporation (US) | 2007-08-22 | — | — | EP | disclosed |
| US-20060223996-A1 | IL-12 modulatory compounds | SYNTA PHARMACEUTICALS CORP. (US) | 2006-10-05 | — | — | US | disclosed |
| WO-2006053227-A2 | IL-12 MODULATORY COMPOUNDS | SYNTA PHARMACEUTICALS CORP. (US) | 2006-05-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060223996-A1 | IL-12 modulatory compounds | IL2, IL4, IFNG | KDM4E 3666/4885TSHR 3812/4885SMN1; SMN2 4828/4885 |
| US-20100256132-A1 | IL-12 MODULATORY COMPOUNDS | IL2, IL4, IFNG | KDM4E 3666/4885TSHR 3812/4885SMN1; SMN2 4828/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.